Biocartis Group NV Cash Flow Conversion Efficiency
Biocartis Group NV cash flow conversion efficiency. Based on the latest financial reports, Biocartis Group NV (BCART) has a cash flow conversion efficiency ratio of 0.542x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-29.29 Million ≈ $-34.24 Million USD) by net assets (€-53.99 Million ≈ $-63.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biocartis Group NV (2012–2022)
Cash flow conversion efficiency of Biocartis Group NV from 2012 to 2022. This chart illustrates how Biocartis Group NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BCART stock price for real-time trading data and today's change.
Biocartis Group NV Cash Flow Conversion Ratio Explained
Biocartis Group NV cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biocartis Group NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biocartis Group NV ranked by their cash flow conversion efficiency. Also see market cap of Biocartis Group NV for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MicroCloud Hologram Inc.
NASDAQ:HOLO
|
0.003x |
|
Jindalee Lithium Ltd
AU:JLL
|
-0.111x |
|
Derluks Yatirim Holding AS
IS:DERHL
|
0.123x |
|
Sunstone Metals Ltd
AU:STM
|
-0.010x |
|
ENVIONEER Co.Ltd
KQ:317870
|
0.015x |
|
Dunia Virtual Online Tbk Pt
JK:AREA
|
0.063x |
|
Kincora Copper Ltd
V:KCC
|
-0.005x |
|
Nova EYE Medical Ltd
AU:EYE
|
-0.059x |
Annual Cash Flow Conversion Efficiency for Biocartis Group NV (2012–2022)
The table below shows the annual cash flow conversion efficiency of Biocartis Group NV from 2012 to 2022. Review BCART financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | €-30.28 Million ≈ $-35.41 Million |
€-44.85 Million ≈ $-52.44 Million |
1.481x | -23.60% |
| 2021-12-31 | €-33.90 Million ≈ $-39.63 Million |
€-65.72 Million ≈ $-76.83 Million |
1.939x | +281.81% |
| 2020-12-31 | €36.82 Million ≈ $43.05 Million |
€-39.27 Million ≈ $-45.91 Million |
-1.066x | -66.04% |
| 2019-12-31 | €84.48 Million ≈ $98.76 Million |
€-54.25 Million ≈ $-63.43 Million |
-0.642x | -33.59% |
| 2018-12-31 | €87.35 Million ≈ $102.12 Million |
€-41.99 Million ≈ $-49.09 Million |
-0.481x | -53.54% |
| 2017-12-31 | €132.24 Million ≈ $154.60 Million |
€-41.41 Million ≈ $-48.41 Million |
-0.313x | +43.10% |
| 2016-12-31 | €96.89 Million ≈ $113.27 Million |
€-53.31 Million ≈ $-62.33 Million |
-0.550x | -170.72% |
| 2015-12-31 | €114.92 Million ≈ $134.35 Million |
€-23.36 Million ≈ $-27.31 Million |
-0.203x | +88.51% |
| 2014-12-31 | €20.28 Million ≈ $23.71 Million |
€-35.88 Million ≈ $-41.95 Million |
-1.769x | -37.31% |
| 2013-12-31 | €31.95 Million ≈ $37.36 Million |
€-41.18 Million ≈ $-48.14 Million |
-1.289x | -14.93% |
| 2012-12-31 | €36.80 Million ≈ $43.02 Million |
€-41.26 Million ≈ $-48.24 Million |
-1.121x | -- |
About Biocartis Group NV
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progres… Read more